logo
Plus   Neg
Share
Email

AccorHotels Reaffirms Ambitions, Targets Doubling Of EBITDA By 2022

AccorHotels (ACRFY.PK,ACRFF.PK) on Tuesday reaffirmed the key components of its strategy in its trading update ahead of its Capital Market Day to be held in Paris.

Further, AccorHotels said it targets the doubling of its EBITDA between 2017 and 2022, to reach 1.2 billion euros. This will be driven by the integration and ramp-up of recent acquisitions, and solid revenue growth, reflecting both sound business levels in the Group's key markets and the continued increase in development, supported by the upscaling of its brand portfolio. The outlook also reflects operating margin improvement, thanks to strict control of central costs.

The company added that operating performance enhancement, combined with stable CAPEX will lead to sharp increase in recurring cash-flows, and hence the Group's dividend per share.

AccorHotels said the execution of its strategy will be fostered by two initiatives: The public tender offer for 47% of the share Capital of the Polish company Orbis that AccorHotels does not own.

Also, the alignment of the company's support functions with its new economic model, notably in Europe, in order to better serve partners and clients, while optimizing central costs, expected to remain stable over the midterm.

In Paris, AccorHotels shares are trading at 40.08 euros, up 1.47 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cargill, a privately-held food and agriculture company, said Monday it will launch new private label plant-based patties and ground products in order to meet the growing global demand for protein. The new products will hit retailers and restaurants in early April. Cargill said that the plant-based protein products were developed through extensive consumer research and innovation. Taro Pharmaceuticals U.S.A., Inc., the U.S.-based business of Israeli Pharma firm Taro Pharmaceutical Industries, Ltd., recalled certain lots of seizure medication Phenytoin in the form of oral suspension for potential underdosing or overdosing, the U.S. Food and Drug Administration said in a statement. The company found that the oral suspension may not re-suspend when shaken. The Federal Trade Commission (FTC) is in the process of sending out refund checks to consumers who were allegedly misled by Office Depot, Inc. and its software provider Support.com, Inc., into buying computer repair products and services. Out of $34 million, being the total amount of checks, Office Depot paid $25 million and Support.com paid $10 million as part of 2019 settlement.
RELATED NEWS
Follow RTT
>